Association of Prescription Co-payment With Adherence to Glucagon-Like Peptide-1 Receptor Agonist and Sodium-Glucose Cotransporter-2 Inhibitor Therapies in Patients With Heart Failure and Diabetes

By sjmartinez • June 2, 2023

Essien UR, Singh B, Swabe G, Johnson AE, Eberly LA, Wadhera RK, Breathett K, Vaduganathan M, Magnani JW. Association of Prescription Co-payment With Adherence to Glucagon-Like Peptide-1 Receptor Agonist and Sodium-Glucose Cotransporter-2 Inhibitor Therapies in Patients With Heart Failure and Diabetes. JAMA Netw Open. 2023 Jun 1;6(6):e2316290. doi: 10.1001/jamanetworkopen.2023.16290. PMID: 37261826.

Tags: General Internal Medicine, Publications, Veterans Administration

Related Posts

Hormone therapy use and duration with postoperative radiotherapy for recurrent prostate cancer: an individual patient data meta-analysis

Kishan AU, Sun Y, Parker CC, Sargos P, Sydes MR, Chabaud S, Brihoum M, Kalbasi TR, Steinberg ML, Valle LF, Taparra K, Shoag JE, Garcia[...]

Combined associations of GLP-1 receptor agonists and a healthy lifestyle with cardiovascular outcomes among individuals with type 2 diabetes: a prospective cohort study

Nguyen XT, Li Y, Czernichow S, Rassy N, Houghton SC, Lu B, Ho YL, Charest BR, Wang DD, Gagnon DR, Gaziano JM, Willett WC, Wilson[...]

Discontinuation of statins by patient and physician sex: An observational study

Watanabe A, Miyamoto Y, Ueyama HA, Gotanda H, Slipczuk L, Inoue K, Secemsky E, Laham R, Bhatt DL, Tsugawa Y, Kuno T. Discontinuation of statins[...]